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Abstract
Amylofeed® is a preparation of endo-1,3(4)-b-glucanase, endo-1,4-b-xylanase and a-amylase aimed to
be used as a feed additive for piglets and young minor porcine species. In a previous assessment, the
safety of the additive for the target species, user and environment were established. However, the
safety for the consumer and the efﬁcacy of the product could not be established. In that previous
assessment, the limitations on the description of the manufacturing process, the characterisation of the
additive and on the toxicological studies provided did not allow the Panel to conclude on the safety for
the consumer. The applicant has now provided new data/information to assess the safety for the
consumer and also new studies in order to support the efﬁcacy of the additive in the target species.
The enzymes present in the product are obtained from two different strains and from two different
fermentation processes. In the current assessment, the applicant provided complete and detailed
information regarding the manufacturing process of the additive, including details on the composition of
the intermediate products. New genotoxicity studies were submitted by the applicant and the results
showed no genotoxic potential of the test items. The Panel considered that the conclusions drawn in
the subchronic oral toxicity study performed and previously submitted were valid for the current
assessment; the results showed no evidence for adverse effects. Consequently, the Panel concluded
that the additive is safe for the consumers when used as a feed additive. For the evaluation of the
efﬁcacy of the additive, the Panel considered four long-term trials done in weaned piglets. Based on
these data, the Panel concluded that the additive has a potential to be efﬁcacious in weaned piglets at
the nominal dose of 500 mg/kg feed and extrapolated this conclusion to growing minor porcine
species.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety of
Amylofeed® (endo-1,3(4)-b-glucanase, endo-1,4-b-xylanase and a-amylase) as a feed additive for
piglets and young minor porcine species.
In 2013, the FEEDAP Panel adopted an opinion on the safety and efﬁcacy of Amylofeed® (endo-1,3
(4)-b-glucanase, endo-1,4-b-xylanase and a-amylase) as a feed additive for piglets and minor porcine
species. The safety of the additive for the target species, user and environment was established at
that time. However, the safety for the consumer and the efﬁcacy of the product could not be
established. The applicant has now provided new data/information and toxicological studies to assess
the safety for the consumer. The applicant submitted also new studies in order to support the efﬁcacy
of the additive in the target species.
The enzymes present in the product are obtained from two different strains and from two different
fermentation processes. In the current assessment, the applicant provided complete and detailed
information regarding the manufacturing process of the additive. Moreover, the applicant provided
supplementary information regarding the composition of the additive, the absence of the production
strain in the ﬁnal product and the content of mycotoxins as well as secondary metabolites of the
production strains.
With the newly provided information on the manufacturing and on the test items used in the
toxicological studies evaluated in 2013, the Panel identiﬁed the need for new genotoxicity studies. New
genotoxicity studies were submitted by the applicant. Due to the characteristics of the manufacturing
process, the applicant prepared extracts of the fermentation products: water and dimethylsulfoxide
extracts were prepared in order to ensure the recovery of any product present in the fermentation
products. The extracts obtained from each fermentation product were tested separately in the
bacterial reverse mutation test and also in the in vitro mammalian cell micronucleus test. The results of
the tests showed no genotoxic potential of the test items. The Panel considered that the conclusions
drawn in the subchronic oral toxicity study performed and previously submitted can be considered
valid for the current assessment; the results showed no evidence of adverse effects.
For the evaluation of the efﬁcacy of the additive, the Panel considered four long-term trials done in
weaned piglets. The data from these four studies were pooled and statistically analysed. The data
showed an improvement on the body weight and on the feed to gain ratio in the piglets fed with the
additive at a nominal dose of 500 mg additive/kg feed. Therefore, the Panel concluded that the
additive has a potential to be efﬁcacious in weaned piglets at the nominal dose of 500 mg/kg feed and
extrapolated this conclusion to growing minor porcine species. The analyses of the enzyme activity in
the diets showed a higher glucanase and xylanase activities compared to the intended ones.
Consequently, the Panel could not conclude on the efﬁcacy at the recommended dose in terms of
enzyme activity.
Amylofeed® for weaned pig and minor porcine species
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/2003 establishes rules governing the Community authorisation of additives
for use in animal nutrition and in particular, Article 9 thereof deﬁnes the terms of such authorisation by
the Commission.
The applicant ANDRES PINTALUBA S.A. is seeking an authorisation of its endo-1,3(4)-b-glucanase
EC 3.2.1.6, endo-1,4-b-xylanase EC.3.2.1.8 and a-amylase EC 3.2.1.1, to be used as zootechnical
additive (Table 1).
On 8th October 2013, the Authority, in its opinion on the safety and efﬁcacy of the product, could
not conclude on the consumer safety based on the toxicological studies provided and the lack of
information on the manufacturing process that led to an insufﬁcient characterisation of the product. In
addition the efﬁcacy of endo-1,3(4)-b-glucanase EC 3.2.1.6, endo-1,4-b-xylanase EC 3.2.1.8 and
a-amylase EC 3.2.1.1 was not demonstrated from the data provided by the applicant.
The Commission gave the possibility to the applicant to submit complementary information in order
to complete the assessment on the safety and efﬁcacy to allow a revision of Authority’s opinion.
The data generated by the applicant and compiled in the above-mentioned supplementary reports
have been sent directly to the Authority.
In view of the above, the Commission asks the Authority to deliver an opinion on safety and
efﬁcacy of endo-1,3(4)-b-glucanase EC 3.2.1.6, endo-1,4-b-xylanase EC 3.2.1.8 and a-amylase EC
3.2.1.1 as zootechnical additive based on the additional data submitted by applicant.
1.2. Additional information
Amylofeed® is an enzyme preparation that contains endo-1,3(4)-b-glucanase, endo-1,4-b-xylanase
and a-amylase. EFSA issued in 2013 an opinion on the use of Amylofeed® as a zootechnical additive
(functional group: digestibility enhancers) for piglets and young minor porcine species (EFSA FEEDAP
Panel, 2013). However, the FEEDAP Panel could not conclude on the safety of the additive for the
consumers and the efﬁcacy of the additive in weaned piglets was not demonstrated.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of supplementary
information1 to a previous application on the same product.2
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety of Amylofeed® is in line with the
principles laid down in Regulation (EC) No 429/20083 and the relevant guidance documents: Guidance
on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical guidance: Tolerance and efﬁcacy
studies in target animals (EFSA FEEDAP Panel, 2011), Technical Guidance: Microbial Studies (EFSA,
Table 1: Description of the substances
Category of additive Zootechnical additives
Functional group of additive Digestibility enhancers
Description Endo-1,3(4)-b-glucanase EC 3.2.1.6
Endo-1,4-b-xylanase EC 3.2.1.8 and a-amylase EC 3.2.1.1
Target animal category Piglets (weaned) and young minor porcine species
Applicant Andres Pintaluba S.A.
Type of request Update opinion
1 FEED dossier reference: FAD-2014-0019.
2 FEED dossier reference: FAD-2010-0353.
3 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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2008), and Guidance for establishing the safety of additives for the consumer (EFSA FEEDAP Panel,
2012b).
3. Assessment
Amylofeed® contains, per gram, a minimum activity of 275 Units (U)4 of endo-1,3(4)-b-glucanase
(glucanase; Enzyme Commission number (EC) 3.2.1.6), 400 U5 of endo-1,4-b-xylanase (xylanase; EC
3.2.1.8) and 3,100 U6 of a-amylase (amylase; EC 3.2.1.1). It is intended to be used as a zootechnical
additive (functional group: digestibility enhancers) for weaned piglets and young minor porcine species
at a recommended dose of 138 glucanase, 200 xylanase and 1,550 amylase U/kg complete feed
(provided by 500 mg additive/kg feed).
In the assessment performed in 2013 (EFSA FEEDAP Panel, 2013), the safety of this additive for
the target species, user and environment were established. However, considering the limitations on the
description of the manufacturing process, the characterisation of the additive and the inadequacies of
the toxicological studies provided the Panel could not conclude on the safety for the consumer.
Moreover, the Panel could not conclude on the efﬁcacy of the additive in the target species. The
applicant has now provided new data/information on the manufacturing process, characterisation of
the additive and toxicological studies in order to assess the safety for the consumer. The applicant
submitted also new studies in order to support the efﬁcacy of the additive in the target species.
3.1. Characterisation7
In the previous assessment (EFSA FEEDAP Panel, 2013), the dossier missed relevant information
regarding the fermentation steps, the characteristics of the resulting products (including the
composition and the presence of the production strains) and on the ﬁnal composition of the additive.
The applicant has now submitted new information.
Amylofeed® contains two fermentation products obtained in independent fermentations, one from
Aspergillus niger NRRL 25541 and another one from Aspergillus oryzae ATTC 66222. The source of the
xylanase and glucanase present in the additive is the fermentation product from A. niger and the source
of amylase is the fermentation product from A. oryzae. The applicant submitted detailed information for
each fermentation process and preparation of the additive including: the different fermentation steps,
composition of the resulting products, the methodologies followed to kill the production strains, while
preserving the xylanase, glucanase and amylase enzyme activities and on the composition of the
additive. The information allowed the Panel to fully characterise the manufacturing process and the
composition of the additive itself. The applicant accompanied the information with data on the batch to
batch variation of the enzyme activity, absence of the production strains and purity data of the additive.
The batch to batch variation in ﬁve batches showed compliance with the minimum speciﬁcations
(mean value of 584 glucanase U/g product (534–616 U/g), 523 U xylanase/g (480–577 U/g) and
5,206 U amylase/g (4,725–5,589 U/g)).8 The presence of the production strains in the ﬁnal product
was evaluated in the same batches of the additive and was not found.
4 1 U is the amount of enzyme that liberates 1 micromole of reducing sugars (glucose equivalents) from oat beta-glucan per
minute at pH 4.0 and 30°C.
5 1 U is the amount of enzyme that liberates 1 micromole of reducing sugars (glucose equivalents) from rye arabinoxylan per
minute at pH 4.0 and 30°C.
6 1 U is the amount of enzyme that liberates 1 micromole of reducing sugars (glucose equivalents) from wheat starch per
minute at pH 5.0 and 30°C.
7 This section has been amended following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003
8 Technical dossier FAD-2014-0019/Annex II.3.6.
Amylofeed® for weaned pig and minor porcine species
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2017;15(6):4856
The substrate for fermentation used to prepare the additive (four batches), the ﬁnal additive (ﬁve
batches) and a water extract of the additive (one batch) were analysed for the presence of
mycotoxins.9 The mycotoxins investigated were found to be below the limit of quantiﬁcation.10,11 One
batch of the additive was analysed for secondary metabolites produced by the two production strains.
The following metabolites that can be produced by A. niger or by A. oryzae were investigated:
malformin C (LOD = 0.1 mg/kg), oxalic acid (23 g/kg), nigragillin (0.2 mg/kg), aurasperone
(not detected, LOD = 500 lg/kg), nigerazines (not detected, LOD = 100 lg/kg), cyclopiazonic acid
(not detected, LOD = 100 lg/kg), 3-nitropropionic acid (not detected, LOD = 800 lg/kg), kojic acid
(not detected, LOD = 600 lg/kg), maltoryzine (not detected, LOD not given), violacetin (not detected,
LOD = 100 lg/kg) and aspergillomarasmine (not detected, LOD not given).12
New studies looking for the presence of antimicrobial activity were provided: the freeze-dried water
extracts of the fermentation products (used in the genotoxicity studies, see below) showed no
antimicrobial activity against ﬁve bacterial strains recommended by EFSA (2008).13 The applicant
declared that no antimicrobial substances are used in the manufacturing process.
3.2. Safety for the consumer7
In the previous assessment (EFSA FEEDAP Panel, 2013), the applicant provided a bacterial reverse
mutation assay, an in vitro micronucleus test and a subchronic oral toxicity study in rat. However, the
Panel could not conclude on the suitability of the studies, due to the characteristics of the test items
used, the unclear relationship with the additive under assessment and the methodologies followed.
With the information provided in the current assessment on the manufacturing and on the test
items used in the studies evaluated in 2013, the Panel identiﬁed the need for new genotoxicity studies
while conﬁrmed the appropriateness of the subchronic oral toxicity studies previously evaluated (see
below). The applicant has provided new genotoxicity studies.
3.2.1. Genotoxicity studies
Owing to the characteristics of the fermentation processes and the resulting products, the applicant
was requested to use extracts of each fermentation product to perform the new genotoxicity tests. To
ensure the complete extraction of possible by-products from the fermentation products, water and
dimethylsulfoxide (DMSO) extracts were prepared. Aliquots of the fermentation products were
separately suspended in water or in DMSO, kept under continuous stirring overnight. The samples
obtained after separation of cells and particles were concentrated by freeze-drying, in the case of the
water extract or by vacuum evaporation at 50°C, in the case of the DMSO extract.
3.2.1.1. Bacterial reverse mutation tests
Fermentation product of Aspergillus niger NRRL 25541
The two extracts were tested separately in Salmonella Typhimurium strains TA1535, TA1537, TA98,
TA100 and TA102 following the OECD Guideline 471.14 The freeze-dried water extract was diluted in
distilled water and tested up to a concentration of 5,000 lg/plate. The DMSO extract was diluted in
DMSO and the maximum concentrations tested were 40 lg/plate or mL, due to a considerable
precipitation that hindered the scoring, although no cytotoxicity was reported. For each extract, two
independent experiments were conducted, with and without metabolic activation (S9 mix from rat
livers induced by Aroclor 1254). The second assay was performed according to the pre-incubation
method with metabolic activation and according to the plate incorporation without metabolic
9 Technical dossier FAD-2014-0019/Supplementary information December 2015/Annexes II.1.4.1, II.1.4.2 and II.1.4.3.
10 The mycotoxins investigated in the substrate and ﬁnal product were: aﬂatoxins B1 (< 5 µg/kg), B2 (< 3 µg/kg), G1 (< 7 µg/kg)
and G2 (< 9 µg/kg), deoxynivalenol (< 100 µg/kg), fumonisin B1 (< 40 µg/kg), B2 (< 100 µg/kg) and B3 (< 80 µg/kg), T-2 toxin
(< 90 µg/kg), HT-2 toxin (< 80 µg/kg), ochratoxin A (< 8 µg/kg), sterigmatocystin (< 4 µg/kg) and zearalenone (< 70 µg/kg).
11 The mycotoxins investigated in the water extract were: aﬂatoxins B1 (< 0.5 µg/kg), B2 (< 0.3 µg/kg), G1 (< 0.7 µg/kg) and
G2 (< 0.9 µg/kg), deoxynivalenol (< 10 µg/kg), fumonisin B1 (< 4 µg/kg), B2 (< 10 µg/kg) and B3 (< 8 µg/kg), T-2 toxin
(< 9 µg/kg), HT-2 toxin (< 8 µg/kg), ochratoxin A (< 0.8 µg/kg), sterigmatocystin (< 0.4 µg/kg), zearalenone (< 7 µg/kg),
diacetoxyscirpenol (< 10 µg/kg), acetyldeoxinivalenol (< 13 µg/kg), ergocristine (< 5 µg/kg), ergocryptine (< 6 µg/kg),
ergosine (< 9 µg/kg), neosolaniol (< 10 µg/kg), nivalenol (< 7 µg/kg), alpha-zearalenol (< 5 µg/kg) and beta-zearalenol
(< 7 µg/kg).
12 Technical dossier FAD-2014-0019/Supplementary information November 2016/Annex II.1.4.5.
13 Technical dossier FAD-2014-0019/Supplementary information December 2015/Annex II.1.4.4.
14 Technical dossier FAD-2014-0019/Supplementary information December 2015/Annex III.2.2.2.6.1 and III.2.2.2.8.1.
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activation. With the DMSO extract and owing to a dosage error in the second experiment, a third
experiment only with metabolic activation (pre-incubation method) was conducted.
With the water extract, neither cytotoxicity nor precipitation was observed. No increase in the
number of revertants over the threshold of biological signiﬁcance (two fold) and/or over historical
control was observed in any experimental condition, while the positive controls produced the expected
mutagenic effect.
With the DMSO extract in the third experiment, a 2.5 times increase in the number of revertants
was noted at the highest dose of 30 lL/mL in strain TA98. This increase was not conﬁrmed in a fourth
experiment performed under the same experimental conditions. No other increase in the number of
revertants was observed. The positive controls performed as expected.
Fermentation product Aspergillus oryzae ATTC 66222
The two extracts were tested separately in Salmonella Typhimurium strains TA1535, TA1537, TA98,
TA100 and TA102 following the OECD Guideline 471.15 The freeze-dried water extract was diluted in
distilled water and tested up to a concentration of 5,000 lg/plate. The DMSO extract was highly
viscous and it was diluted in DMSO and the maximum concentrations tested were 10 lL/plate or mL.
For each extract, two independent experiments were conducted, with and without metabolic activation
(S9 mix from rat livers induced by Aroclor 1254). The second assay was performed according to the
pre-incubation method with metabolic activation and according to the plate incorporation without
metabolic activation.
In the water extract, neither cytotoxicity nor precipitation was observed, but some opacity,
attributed to the presence of histidine in the test item, was reported at the top concentration.
Statistically signiﬁcant increases in the number of revertant colonies were noted in strain TA102
without metabolic activation, and in strains TA1535 and TA100 with metabolic activation with
pre-incubation. However, these increases were attributed to the presence of traces of histidine in the
test item. In fact, no such increase was reported when the treat and wash method, that allows the
elimination of peptides and amino acids from the medium, was applied. In the DMSO extract, under
the experimental conditions applied, no mutagenic activity was revealed.
3.2.1.2. In vitro micronucleus test
Fermentation product Aspergillus niger NRRL 25541
The two extracts were tested separately in the in vitro mammalian cell micronucleus test on TK6
lymphoblastoid human cells, following the OECD Guideline 487.16 The freeze-dried water extract was
diluted in distilled water and a top concentration of 2,000 lg/mL was selected on the basis of a
preliminary cytotoxicity test. The DMSO extract was diluted in DMSO and the test concentrations were
deﬁned as percentages; the top concentration was 0.5%, based on a preliminary cytotoxicity test. The
following treatment schedules were used: 3 h treatment followed by 24 h recovery time, with and
without metabolic activation (S9 mix from rat livers induced by Aroclor 1254); 27 hours continuous
treatment without recovery time, only without metabolic activation. Two independent cultures were
used and 1,000 cells per culture per concentration were scored.
The two extracts did not induce any statistically signiﬁcant increase in the number of
micronucleated cells at any of the concentrations analysed, while the positive controls were clearly
effective, showing the sensitivity of the test system.
Fermentation product Aspergillus oryzae ATTC 66222
The two extracts were tested separately in the in vitro mammalian cell micronucleus test on TK6
lymphoblastoid human cells, following the OECD Guideline 487.17 The freeze-dried water extract was
diluted in distilled water and the DMSO extract was diluted in DMSO. The top concentration tested was
limited by the cytotoxicity of the test item. The treatment schedules followed OECD guideline
recommendation as reported above and 1,000 cells per concentration per two independent culture were
scored. The two extracts showed negative results, while the positive controls performed as expected.
15 Technical dossier FAD-2014-0019/Supplementary information December 2015/Annex III.2.2.2.6.2 and III.2.2.2.8.2.
16 Technical dossier FAD-2014-0019/Supplementary information December 2015/Annexes III.2.2.2.7.1 and III.2.2.2.9.1.
17 Technical dossier FAD-2014-00189/Supplementary information December 2015/Annexes III.2.2.2.7.2 and III.2.2.2.9.2.
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3.2.2. Subchronic oral toxicity study
In the previous assessment, the applicant provided a subchronic oral toxicity study in rats (EFSA
FEEDAP Panel, 2013). In that study, the rats were fed the additive, Amylofeed®, instead of the
fermentation products used to formulate the additive as recommended by the Guidance for
establishing the safety of additives for the consumer (EFSA FEEDAP Panel, 2012b). However, with the
limited information previously submitted, the Panel could not conclude on the suitability of the test
item. The supplementary information submitted in the current assessment allows the Panel to conclude
that in this case the use of the additive is valid. In particular, considering the manufacturing process,
resulting product and the highest treatment concentration the actual treatment dosage for the two
fermentation products can be considered sufﬁcient. The results showed that there is no evidence for
adverse effects.
3.2.3. Conclusions on the safety for the consumer
The results obtained in the genotoxicity studies and in the subchronic oral toxicity studies
considered do not indicate any reason for concern for consumer safety arising from the use of the
product as a feed additive.
3.3. Efﬁcacy in the target species
The additive is to be used in feed for piglets and young minor porcine species at a recommended
dose of 138 glucanase, 200 xylanase and 1,550 amylase U/kg complete feed (provided by 500 mg
additive/kg feed).
In 2013, the Panel evaluated ﬁve trials in weaned piglets (EFSA FEEDAP Panel, 2013). Four of them
were rejected due to the use of medication and/or due to the short duration of the studies. One of the
studies was retained as acceptable and has been also included in the current assessment (trial 1
below). A total of ﬁve trials were assessed in the current assessment, four of which were newly
submitted. One of these trials was not considered due to the limitations found in the study design; the
diets containing the additive were different in terms of composition to the one in the control diet, not
representing therefore a suitable control.18 A summary of the trial design is presented in Table 2 and
the results are presented in Table 3. In the four studies, weaned piglets were used and the
experimental groups considered a control diet and at least a diet with the recommended dose of the
additive. The diets were analysed for enzyme activities and the results are reported in Table 3. Before
the start of the study, the piglets in trials 2–4 were allowed for a short period (from 2 to 6 days) of
acclimatisation to the rooms and diets. The duration of all the studies was of 42 days. Health was
monitored throughout the duration of the studies. Feed intake and body weight were measured and
feed to gain were calculated. In trial 4, a digestibility study was conducted but the data is not reported
because the effect on the metabolisable energy content was not evaluated. In each individual study,
the data was analysed by an ANOVA, using the pen as the experimental unit and considering the
effect of the sex where relevant.
18 Technical dossier FAD-2014-0019/Supplementary information December 2015/Annex IV.3.6.
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The results of the individual studies showed a signiﬁcant improvement on the ﬁnal body weight in two
trials (trials 1 and 2) and on the feed to gain ratio in one trial (trial 2) at the recommended dose (nominal
basis). In trial 3, there was an interaction between the treatment and the sex; signiﬁcant improvement
on the body weight of the piglets at the recommended dose (nominal basis) was seen only in males.
The applicant pooled the data of the four studies considering the control groups and the group with
the recommended dose.19 The effects of the treatment and of the study were included in the model as
well as their interaction. No interactions between treatment and study were found. The results showed a
higher ﬁnal body weight (27.1 vs 26.3 kg, p < 0.05) and a better feed to gain ratio (1.59 vs 1.64,
p < 0.05) in the group receiving the recommended dose. The Panel notes that analytical results of the
enzyme activity in the diets showed a large overage in glucanase and xylanase in trials 2, 3 and 4. The
mean values for glucanase and xylanase in those trials were 445 and 596 U/kg feed, respectively,
whereas the intended doses are 138 and 200 U/kg feed for glucanase and xylanase, respectively.
Table 2: Trial design and dosages of the efﬁcacy trials performed in weaned piglets
Trial
Total no animals
(animals/replicate)
Replicates/group
Breed
Sex
Initial BW
Diet composition (form)
Enzyme activity (U/kg) Glucanase/
xylanase/amylase
Intended Analysed
1(a) 640
(10)
16
Large White 9 Landrace
♀,♂ mixed 50:50
7.7 kg
Barley, wheat, maize, soya
bean meal
(pellets)
0/0/0
110/160/1,240
138/200/1,550
165/240/1,860
0/0/0
116/105/744
281/160/1,091
199/178/1,337
2(b) 144
(4)
18
Goland 9 Duroc BM
♀,♂castrated, sex separated
7.5 kg
Maize, soya bean meal
(mash)
0/0/0
138/200/1,550
0/0/0
620/562/1,872
3(c) 144
(4)
18
Bompieri 9 Goland
♀,♂castrated, sex separated
7.1 kg
Maize, soya bean meal
(mash)
0/0/0
138/200/1,550
7/84/0
378/507/1,056
4(d) 144
(6)
12
Commercial breed
♀,♂ mixed
7.9 kg
Barley, wheat, soya bean
meal
(mash)
0/0/0
138/200/1,550
0/0/0
338/719/1,542
(a): Technical dossier FAD-2014-0019/Annex IV.3.1.
(b): Technical dossier FAD-2014-0019/Supplementary information December 2015/Annex IV.3.7.
(c): Technical dossier FAD-2014-0019/Supplementary information November 2016/Annex IV.3.8.
(d): Technical dossier FAD-2014-0019/Supplementary information January 2017/Annex IV.3.9.
Table 3: Effects of Amylofeed on the performance of weaned piglets
Trial
Enzyme activity
(U/kg)
Daily feed
intake (kg)
Body weight (kg)
Feed to gain ratio Dead (n)
Initial Final
1 0/0/0 0.676 7.8 25.4a 1.61 2
110/160/1,240 0.689 7.8 26.0a,b 1.59 3
138/200/1,550 0.685 7.8 26.4a 1.55 0
165/240/1,860 0.678 7.8 25.5b 1.61 3
2 0/0/0 0.850 7.6 27.8b 1.76a 0
138/200/1,550 0.840 7.4 28.9a 1.65b 0
3 0/0/0 0.760 7.0 25.9 1.69 0
138/200/1,550 0.772 7.2 26.4 1.69 0
4 0/0/0 0.606 7.9 25.9 1.42 2
138/200/1,550 0.620 7.9 26.2 1.42 1
Pooled data 0/0/0 0.736 7.5 26.3b 1.64a 
138/200/1,550 0.740 7.5 27.1a 1.59b 
a,b: Values within one column for the same study with different superscripts are different (p < 0.05).
19 Technical dossier FAD-2014-0019/Supplementary information January 2017/Annex IV.3.10.
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The Panel concludes based on the results from the pooling study that the additive has a potential to
be efﬁcacious in weaned piglets at the nominal dose of 500 mg additive/kg feed. The mode of action is
well known and it is assumed to be similar among porcine species, consequently, this conclusion can be
extrapolated to growing minor porcine species. However, considering the analysed enzyme activities in
feed, the Panel is not in a position to conclude on the effective doses in terms of enzyme activities.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation20 and Good
Manufacturing Practice.
4. Conclusions
The use of Amylofeed® as a feed additive does not give rise to safety concerns for consumers.
Amylofeed® has a potential to be efﬁcacious as a zootechnical additive in weaned piglets and
growing minor porcine species at a nominal dose of 500 mg additive/kg feed. However, considering
the analysed enzyme activities in feed, the Panel is not in a position to conclude on the effective doses
in terms of enzyme activities.
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